Margaret Lawson

Senior Scientist, CHEO Research Institute

Dr. Margaret Lawson is a pediatric endocrinologist at CHEO, Senior Investigator at the CHEO Research Institute, and Professor of Pediatrics at the University of Ottawa. Her research focuses on type 1 diabetes in children and youth, its prevention, and its management – particularly the use of technologies such as insulin pump therapy and continuous glucose monitoring. Her other main research interest focuses on acquiring evidence about the medical, social and family outcomes of hormone intervention for transgender and gender non binary youth.

Email Researcher

Research Areas

Endocrinology Gender Diversity Diabetes Health Data Neonatal Intensive Care Adrenal Insufficiency Vitamin D Intensive Care

Related News

  1. Trans Youth CAN! reinforces need for better access to gender-affirming care and mental health support

    26/07/2022

    Trans Youth CAN! reinforces need for better access to gender-affirming care and mental health support

  2. 2021 CHEO Research Institute Annual Report

    14/06/2022

    2021 CHEO Research Institute Annual Report

  3. CHEO Research Institute Presents Trans Youth Study Results Via Zoom to the Media

    18/08/2020

    CHEO Research Institute Presents Trans Youth Study Results Via Zoom to the Media

Read More News

Research Projects

  1. Pubertal Suppression, Bone Mass and Body Composition in Youth with Gender Dysphoria

    01/10/2021

    The majority of transgender youth had vitamin D insufficiency or deficiency with baseline status associated with bone mineral density. Vitamin D supplementation should be considered for all youth with GD.

  2. Timing of CGM initiation in pediatric diabetes: The CGM TIME Trial

    23/10/2020

    CGM adherence was higher after 6 months when initiated at same time as pump therapy compared to starting CGM 6 months after pump therapy. Greater CGM adherence was associated with improved HbA1c.

  3. Barriers and Facilitators of Pediatric Shared Decision-Making: A Systematic Review

    01/01/2019

    Our findings can be used to identify potential pediatric SDM barriers and facilitators, guide context-specific barrier and facilitator assessments, and inform interventions for implementing SDM in pediatric practice.

  4. Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes: The TRIGR Randomized Clinical Trial

    01/01/2018

    Among infants at risk for type 1 diabetes, weaning to a hydrolyzed formula compared with a conventional formula did not reduce the cumulative incidence of type 1 diabetes after median follow-up for 11.5 years. These findings do not support a need to revise the dietary recommendations for infants at risk for type 1 diabetes.

  5. New Intrauterine Growth Curves Based on United States Data

    01/01/2010

    Final sample included 257 855 singleton infants (57.2% male) who survived to discharge.